CY1121049T1 - Καινοτομες αλληλουχιες σηματος για τη βελτιωση των πρωτεϊνικων εκφρασεων και της εκκρισης των ανασυνδυασμενων ενζυμων και αλλων πρωτεϊνων - Google Patents
Καινοτομες αλληλουχιες σηματος για τη βελτιωση των πρωτεϊνικων εκφρασεων και της εκκρισης των ανασυνδυασμενων ενζυμων και αλλων πρωτεϊνωνInfo
- Publication number
- CY1121049T1 CY1121049T1 CY181100941T CY181100941T CY1121049T1 CY 1121049 T1 CY1121049 T1 CY 1121049T1 CY 181100941 T CY181100941 T CY 181100941T CY 181100941 T CY181100941 T CY 181100941T CY 1121049 T1 CY1121049 T1 CY 1121049T1
- Authority
- CY
- Cyprus
- Prior art keywords
- signal sequences
- bip
- heavy chain
- binding protein
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/10—Energy storage using batteries
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41592610P | 2010-11-22 | 2010-11-22 | |
| PCT/US2011/061862 WO2012071422A2 (en) | 2010-11-22 | 2011-11-22 | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121049T1 true CY1121049T1 (el) | 2019-12-11 |
Family
ID=46146394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY181100941T CY1121049T1 (el) | 2010-11-22 | 2018-09-12 | Καινοτομες αλληλουχιες σηματος για τη βελτιωση των πρωτεϊνικων εκφρασεων και της εκκρισης των ανασυνδυασμενων ενζυμων και αλλων πρωτεϊνων |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9279007B2 (enExample) |
| EP (2) | EP2643468B1 (enExample) |
| JP (1) | JP2014503198A (enExample) |
| KR (2) | KR20190060888A (enExample) |
| CN (1) | CN103328649B (enExample) |
| BR (1) | BR112013012671B1 (enExample) |
| CA (1) | CA2818689C (enExample) |
| CY (1) | CY1121049T1 (enExample) |
| DK (2) | DK2643468T3 (enExample) |
| ES (2) | ES2687415T3 (enExample) |
| HR (1) | HRP20181315T1 (enExample) |
| HU (1) | HUE039070T2 (enExample) |
| LT (1) | LT2643468T (enExample) |
| PL (1) | PL2643468T3 (enExample) |
| PT (1) | PT2643468T (enExample) |
| RS (1) | RS57601B1 (enExample) |
| SI (1) | SI2643468T1 (enExample) |
| SM (1) | SMT201800466T1 (enExample) |
| WO (1) | WO2012071422A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2763526T3 (es) | 2014-07-03 | 2020-05-29 | Hoffmann La Roche | Sistemas de expresión de polipéptidos |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| CN110831961B (zh) | 2017-03-03 | 2024-01-02 | 黑曜石疗法公司 | 用于免疫疗法的cd19组合物和方法 |
| ES3065816T3 (en) | 2017-06-07 | 2026-05-08 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| KR20200090889A (ko) | 2017-11-30 | 2020-07-29 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Cdkl5 발현 변이체 및 cdkl5 융합 단백질 |
| CN112040985A (zh) | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | 用于递送治疗性蛋白质的方法和组合物 |
| JP7749322B2 (ja) | 2018-04-30 | 2025-10-06 | アミカス セラピューティックス インコーポレイテッド | 遺伝子治療構築物及び使用方法 |
| BR112020023145A2 (pt) | 2018-05-17 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| EA202190999A1 (ru) | 2018-10-10 | 2021-10-15 | Амикус Терапьютикс, Инк. | Композиции на основе полипептидов, стабилизированных с помощью дисульфидной связи, и способы применения |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| SG11202105267VA (en) * | 2018-12-19 | 2021-07-29 | Versameb Ag | Rna encoding a protein |
| KR20210149251A (ko) | 2019-03-08 | 2021-12-08 | 옵시디안 테라퓨틱스, 인크. | 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법 |
| CA3134485A1 (en) * | 2019-04-30 | 2020-11-05 | James M. Wilson | Compositions useful for treatment of pompe disease |
| JP2022537670A (ja) | 2019-06-12 | 2022-08-29 | オブシディアン セラピューティクス， インコーポレイテッド | Ｃａ２の組成物および調整可能な制御方法 |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CA3156506A1 (en) * | 2019-10-30 | 2021-05-06 | Amicus Therapeutics, Inc. | Recombinant cdkl5 proteins, gene therapy and production methods |
| CN112342247B (zh) * | 2020-11-10 | 2022-03-11 | 江苏科技大学 | 一种提高家蚕细胞表达外源蛋白分泌率的方法 |
| MX2023006445A (es) | 2020-12-01 | 2023-08-10 | Univ Pennsylvania | Composiciones y usos de estas para el tratamiento del síndrome de angelman. |
| WO2023086939A1 (en) | 2021-11-12 | 2023-05-19 | Amicus Therapeutics, Inc. | Compositions and methods for treating mucopolysaccharidosis iiia |
| WO2025264978A2 (en) | 2024-06-20 | 2025-12-26 | Amicus Therapeutics, Inc. | Recombinant alpha-galactosidase a proteins and gene therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2352286C (en) * | 1998-11-24 | 2011-07-12 | Bristol-Myers Squibb Company | Intracellular targeted delivery of compounds by 70 kd heat shock protein |
| US7279564B2 (en) * | 2003-11-06 | 2007-10-09 | Genencor International, Inc. | Expression in filamentous fungi of protease inhibitors and variants thereof |
| DE602007007923D1 (de) * | 2006-04-11 | 2010-09-02 | Csl Behring Gmbh | Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide |
-
2011
- 2011-11-22 DK DK11843849.8T patent/DK2643468T3/en active
- 2011-11-22 CA CA2818689A patent/CA2818689C/en active Active
- 2011-11-22 DK DK18181451.8T patent/DK3461905T3/da active
- 2011-11-22 PT PT11843849T patent/PT2643468T/pt unknown
- 2011-11-22 JP JP2013541026A patent/JP2014503198A/ja not_active Withdrawn
- 2011-11-22 US US13/988,946 patent/US9279007B2/en active Active
- 2011-11-22 SM SM20180466T patent/SMT201800466T1/it unknown
- 2011-11-22 SI SI201131554T patent/SI2643468T1/sl unknown
- 2011-11-22 LT LTEP11843849.8T patent/LT2643468T/lt unknown
- 2011-11-22 PL PL11843849T patent/PL2643468T3/pl unknown
- 2011-11-22 RS RS20180986A patent/RS57601B1/sr unknown
- 2011-11-22 CN CN201180065369.5A patent/CN103328649B/zh active Active
- 2011-11-22 KR KR1020197015057A patent/KR20190060888A/ko not_active Ceased
- 2011-11-22 HR HRP20181315TT patent/HRP20181315T1/hr unknown
- 2011-11-22 KR KR1020137016110A patent/KR101984318B1/ko active Active
- 2011-11-22 BR BR112013012671-0A patent/BR112013012671B1/pt not_active IP Right Cessation
- 2011-11-22 EP EP11843849.8A patent/EP2643468B1/en active Active
- 2011-11-22 WO PCT/US2011/061862 patent/WO2012071422A2/en not_active Ceased
- 2011-11-22 ES ES11843849.8T patent/ES2687415T3/es active Active
- 2011-11-22 ES ES18181451T patent/ES2829199T3/es active Active
- 2011-11-22 HU HUE11843849A patent/HUE039070T2/hu unknown
- 2011-11-22 EP EP18181451.8A patent/EP3461905B1/en active Active
-
2018
- 2018-09-12 CY CY181100941T patent/CY1121049T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2643468T1 (sl) | 2018-10-30 |
| US9279007B2 (en) | 2016-03-08 |
| PT2643468T (pt) | 2018-10-11 |
| PL2643468T3 (pl) | 2018-11-30 |
| BR112013012671B1 (pt) | 2022-03-03 |
| JP2014503198A (ja) | 2014-02-13 |
| ES2687415T3 (es) | 2018-10-25 |
| WO2012071422A2 (en) | 2012-05-31 |
| EP2643468B1 (en) | 2018-07-04 |
| CA2818689A1 (en) | 2012-05-31 |
| EP3461905A1 (en) | 2019-04-03 |
| SMT201800466T1 (it) | 2018-11-09 |
| WO2012071422A3 (en) | 2012-08-02 |
| KR101984318B1 (ko) | 2019-05-31 |
| BR112013012671A2 (pt) | 2016-10-11 |
| RS57601B1 (sr) | 2018-11-30 |
| CN103328649B (zh) | 2016-06-22 |
| KR20130121878A (ko) | 2013-11-06 |
| EP2643468A2 (en) | 2013-10-02 |
| DK2643468T3 (en) | 2018-09-24 |
| CN103328649A (zh) | 2013-09-25 |
| CA2818689C (en) | 2021-09-21 |
| HUE039070T2 (hu) | 2018-12-28 |
| EP3461905B1 (en) | 2020-08-05 |
| EP2643468A4 (en) | 2014-12-24 |
| US20140045216A1 (en) | 2014-02-13 |
| HRP20181315T1 (hr) | 2018-10-19 |
| DK3461905T3 (da) | 2020-11-02 |
| KR20190060888A (ko) | 2019-06-03 |
| LT2643468T (lt) | 2018-09-10 |
| ES2829199T3 (es) | 2021-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012071422A3 (en) | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins | |
| CY1122250T1 (el) | Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων | |
| CY1118576T1 (el) | Πρωτεϊνες δεσμευομενες με αντιγονο ανθρωπινης il-23 | |
| JP2016501535A5 (enExample) | ||
| CY1113153T1 (el) | ΙL-1β ΔΕΣΜΕΥΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΚΑΙ ΘΡΑΥΣΜΑΤΑ ΑΥΤΩΝ | |
| WO2013075066A3 (en) | Variant serum albumin with improved half -life and other properties | |
| CY1113089T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma) | |
| EA201000357A1 (ru) | Антигенсвязывающие белки, связывающие с-fms человека | |
| MX351502B (es) | Anticuerpos de union de albumina y fragmentos de union de los mismos. | |
| JP2014503198A5 (enExample) | ||
| EA200870555A1 (ru) | Слитые белки, их применение и способы их получения | |
| JP2014221801A5 (enExample) | ||
| EA200700917A1 (ru) | Способ рефолдинга рекомбинантных антител | |
| EA201171259A1 (ru) | Антительные гибридные белки с модифицированными сайтами связывания fcrn | |
| CY1119539T1 (el) | Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1 | |
| MX348071B (es) | Variantes de fc. | |
| DE60335000D1 (de) | In vitro peptid-expressionsbank | |
| WO2006113546A3 (en) | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers | |
| MX380352B (es) | Proteinas de union multivalentes monocatenarias con funcion efectora. | |
| ATE527345T1 (de) | Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten | |
| BRPI0411854A (pt) | veìculos protéicos para vacinas | |
| IS2786B (is) | Prótín sem bindast viðtaka Nogo | |
| CY1117283T1 (el) | Σταθερα μονομερη και ολιγομερη αμυλοειδους βητα | |
| ATE474917T1 (de) | Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide | |
| DE602005027399D1 (de) | Für humane matriptase spezifische bindungsproteine |